Clinical Validation of the RENISCHEM L-FABP POC Assay
Condition: Acute Kidney Injury · Contrast-induced Nephropathy · Sponsor: Hikari Dx, Inc.
About this study
This study will involve measurement of levels of a novel urinary biomarker of renal ischemia, L-FABP. The purpose of the study is to perform a clinical validation of the ability of L-FABP measurements in urine using the RENISCHEM L-FABP POC Test to predict the development of AKI within 2 days following cardiac and vascular catheterization procedures involving exposure to radiocontrast media.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (6)
| Chandler Regional Medical Center | Chandler, Arizona, United States | — |
| John Muir Health | Concord, California, United States | — |
| Clearwater Cardiovascular Consultants | Clearwater, Florida, United States | — |
| University of Florida at Jacksonville | Jacksonville, Florida, United States | — |
| Sinai Hospital of Baltimore | Baltimore, Maryland, United States | — |
| University of Oklahoma | Oklahoma City, Oklahoma, United States | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04864847